SCHEMBL26640862

SCHEMBL26640862

CN(C)CCN(C(=O)OC(C)(C)C)c1ccc(N)cn1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PHLPP2 Q6ZVD8 1/20 0.36
CKS1B P61024 1/20 0.33
SKP1 P63208 1/20 0.33
SKP2 Q13309 1/20 0.33
AAK1 Q2M2I8 2/20 0.32
HDAC1 Q13547 2/20 0.32
HDAC3 O15379 1/20 0.32
HDAC2 Q92769 1/20 0.32
HDAC10 Q969S8 1/20 0.32
NCOR2 Q9Y618 1/20 0.32
GPR119 Q8TDV5 1/20 0.32
SSTR4 P31391 1/20 0.32
HCAR3 P49019 1/20 0.32
HRH3 Q9Y5N1 1/20 0.32
ROCK2 O75116 1/20 0.32
PDK2 Q15119 1/20 0.31
AOC3 Q16853 1/20 0.31
HDAC8 Q9BY41 1/20 0.31
HDAC6 Q9UBN7 1/20 0.31
ALDH1A1 P00352 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30648808 1.00 PHLPP2 (0.36) PHLPP2CKS1BSKP1SKP2AAK1
SCHEMBL23620907 0.95 SSTR4 (0.34) CKS1BSKP1SKP2AAK1HDAC1
SCHEMBL29392374 0.95 SSTR4 (0.34) CKS1BSKP1SKP2AAK1HDAC1
SCHEMBL18519393 0.86 CSNK2A1 (0.35) SSTR4ALDH1A1F2CSNK2A2CSNK2A1
SCHEMBL19674226 0.85 AOC3 (0.34) AAK1HDAC1GPR119SSTR4HCAR3
SCHEMBL29392135 0.82 CKS1B (0.36) CKS1BSKP1SKP2AAK1HDAC1
SCHEMBL56808 0.81 TTK (0.37) CKS1BSKP1SKP2AAK1GPR119
SCHEMBL26640360 0.81 PKM (0.46) ALDH1A1
SCHEMBL11446424 0.80 PHLPP2 (0.37) PHLPP2HDAC1HDAC3HDAC2HDAC10
SCHEMBL55543 0.80 PHLPP2 (0.43) PHLPP2AAK1HRH3ROCK2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4522618-A1 TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES COMPOUNDS AS HPK1 INHIBITORS Merck Patent GmbH (DE) 2025-03-19 EP disclosed
US-20240025922-A1 TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS MERCK HEALTHCARE KGAA (DE) 2024-01-25 US disclosed
US-20240025922-A1 TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS MERCK HEALTHCARE KGAA (DE) 2024-01-25 US disclosed
US-20240025922-A1 TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS MERCK HEALTHCARE KGAA (DE) 2024-01-25 US disclosed
WO-2023220541-A1 TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES COMPOUNDS AS HPK1 INHIBITORS MERCK PATENT GMBH (DE) 2023-11-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240025922-A1 TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS PDXK, DTYMK, HIPK1 PHLPP2 664/4885CKS1B 346/4885SKP1 195/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.